Stunning 28.3% Weight Loss: How Over 45% of Participants Dropped 30+ lbs in Study
Eli Lilly’s Retatrutide Achieves 28.3% Weight Loss in Phase 3 Trials—But What Does It Mean for Patients? Eli Lilly’s experimental peptide retatrutide (a triple-agonist targeting GLP-1, GIP, and glucagon receptors) ... Read More